Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Huls, Gerwin  [Clear All Filters]
Journal Article
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2023;10(11):e879-e889.
Rojas CAlexander, Pereira-Martins DAntonio, More CChristie B, Sternadt D, Weinhäuser I, Hilberink JR, Coelho-Silva JLuiz, Thomé CHassibe, Ferreira GAguiar, Ammatuna E, et al. A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction. Br J Haematol. 2024.
de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. PLoS One. 2019;14(3):e0213913.
Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leuk Res. 2018;72:20-26.
Brink M, Meeuwes FO, van der Poel MWM, Kersten MJosé, Wondergem M, Mutsaers PGNJ, Böhmer LH, Woei-A-Jin FJSherida, Visser O, Oostvogels R, et al. Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study.. Blood. 2022.
Cunningham A, Oudejans LL, Geugien M, Pereira-Martins DAntonio, Wierenga ATJ, Erdem A, Sternadt D, Huls G, Schuringa JJacob. The nonessential amino acid cysteine is required to prevent ferroptosis in acute myeloid leukemia. Blood Adv. 2024;8(1):56-69.
Hout FEMIn 't, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, et al. TCF4 promotes erythroid development. Exp Hematol. 2018.